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Abstract 
Inflammation may contribute to multiple brain pathologies. One cause of inflammation is lipopolysaccharide/endo-
toxin (LPS), the levels of which are elevated in blood and/or brain during bacterial infections, gut dysfunction and 
neurodegenerative diseases, such as Parkinson’s disease. How inflammation causes neuronal loss is unclear, but one 
potential mechanism is microglial phagocytosis of neurons, which is dependent on the microglial  P2Y6 receptor. We 
investigated here whether the  P2Y6 receptor was required for inflammatory neuronal loss. Intraperitoneal injection of 
LPS on 4 successive days resulted in specific loss of dopaminergic neurons (measured as cells staining with tyros-
ine hydroxylase or NeuN) in the substantia nigra of wild-type mice, but no neuronal loss in cortex or hippocampus. 
This supports the hypothesis that neuronal loss in Parkinson’s disease may be driven by peripheral LPS. By contrast, 
there was no LPS-induced neuronal loss in  P2Y6 receptor knockout mice. In vitro, LPS-induced microglial phagocy-
tosis of cells was prevented by inhibition of the  P2Y6 receptor, and LPS-induced neuronal loss was reduced in mixed 
glial–neuronal cultures from  P2Y6 receptor knockout mice. This supports the hypothesis that microglial phagocytosis 
contributes to inflammatory neuronal loss, and can be prevented by blocking the  P2Y6 receptor, suggesting that  P2Y6 
receptor antagonists might be used to prevent inflammatory neuronal loss in Parkinson’s disease and other brain 
pathologies involving inflammatory neuronal loss.
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Background
Inflammation contributes to the pathology and neuronal 
loss of various CNS diseases [1–4], but the mechanisms 
are unclear, and thus means to prevent inflammatory 
neuronal loss are underdeveloped. The inflammatory 
response of the brain is mainly mediated by micro-
glia, which are resident brain macrophages that when 
inflamed can kill neurons by multiple mechanisms, 
including by phagocytosing neurons [1–3]. Dead neurons 
do not accumulate significantly in neurodegenerative dis-
eases, and one potential cause of this is that neurons are 
phagocytosed when alive [5, 6]. Phagocytosis of live cells 
normally results in death of the engulfed cells, a type of 
cell death termed phagoptosis, i.e., cell death by phagocy-
tosis [7]. We have shown that activated microglia become 
highly phagocytic and cause neuronal loss by phagocyto-
sis of stressed-but-viable neurons [8–11].
One cause of inflammation is lipopolysaccha-
ride/endotoxin (LPS), derived from the cell wall of 
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gram-negative bacteria, which activates inflammation 
via Toll-like receptor 4 (TLR4) on immune cells, such as 
microglia [12]. A variety of conditions, such as liver cir-
rhosis, gingivitis, sepsis and Alzheimer’s disease elevate 
plasma LPS levels, and eventually cause neurodegen-
eration [12]. One cause of elevated LPS is infection with 
gram-negative bacteria, and bacterial infections are com-
mon in patients with neurodegenerative diseases and can 
both exacerbate clinical symptoms and accelerate dis-
ease progression [13, 14]. Recently, it was reported that 
plasma LPS levels were substantially elevated in a subset 
of Parkinson’s disease patients, particularly those at high 
risk of dementia [15]. Gut dysfunction is one of the ear-
liest symptoms of Parkinson’s disease, and may result in 
translocation of LPS from the gut (where levels are very 
high) into the blood (where levels are normally very low) 
[12, 15, 16]. Addition of LPS (at levels found in disease) to 
the blood of healthy volunteers results in rapid body and 
brain inflammation with microglial activation [17]. This 
all supports the hypothesis that LPS and microglial acti-
vation contribute to neurodegeneration [12], but further 
evidence and mechanisms are required before potential 
treatments can be devised.
Microglial phagocytosis of neurons requires the  P2Y6 
receptor  (P2Y6R), encoded by the P2ry6 gene, and acti-
vated by extracellular uridine diphosphate (UDP) [18, 
19]. In the brain,  P2Y6R is almost exclusively expressed by 
microglia [18, 20, 21]. The human P2RY6 gene is highly 
homologous to the mouse gene [22, 23], and GWAS data 
indicate that variants of the human gene are associated 
with cognitive performance [24], consistent with a role 
in brain development or neuroprotection. P2ry6 gene 
expression levels were elevated in monocytes from Par-
kinson’s disease patients, and expression was increased 
in a microglial cell line treated with LPS [25]. Microglial 
 P2Y6R has been found to mediate microglial phagocyto-
sis of kainite-treated neurons, which released UTP/UDP 
that activated  P2Y6R on microglia, inducing engulfment 
of these neurons [18]. However, in that work, it was 
assumed that the neurons releasing UDP were dying, 
and it was not determined whether inhibiting  P2Y6R pre-
vented neuronal loss [18]. We found that an inhibitor of 
 P2Y6R (MRS2578) prevented neuronal loss induced by 
LPS injected into brain or cell cultures [9], but we did not 
test whether: (i) this was mediated by  P2Y6R, and (ii) lack 
of  P2Y6R was protective against peripheral LPS. The work 
described here seeks to determine whether the inflam-
matory neuronal loss induced by peripheral LPS can be 
prevented by blocking the microglial  P2Y6 receptor. The 
work shows that peripheral LPS specifically induces neu-
ronal loss in the substantia nigra, and this neuronal loss 
is fully prevented by P2ry6 knockout. This suggests that 
microglial phagocytosis contributes to inflammatory 
neuronal loss, and that blocking  P2Y6R might be neuro-
protective in Parkinson’s disease.
Methods
Animals
P2ry6 knockout (P2ry6−/−) mice were kindly provided 
by Bernard Robaye (ULB Brussels) and maintained on 
a C57Bl/6 background (Charles River Laboratories). 
P2ry6−/− mice and wild-type (WT) littermates were used 
to establish homozygous WT and P2ry6−/− sub-lines. In 
offspring from these sub-lines, littermates were randomly 
assigned to control and LPS treatment groups. Details 
of experimental animals used for each study are given in 
Table 1.
Intraperitoneal injection of LPS
LPS from Salmonella abortus equi (S-form; Enzo Life 
Sciences) or PBS (control) was injected intraperitoneally 
at a dose of 1 µg/g/day in a total volume of 100 µl at the 
same time of day on 4 subsequent days. Animals were 
sacrificed 14 days after the final LPS injection.
Table 1 Details of experimental animals used
Study Treatment group Genotype Number of 
animals
Sex Age range 
(weeks)
Weight range at 
start of procedure 
(g)
I.p. injection of LPS (group 1) Control WT 4 Male 17–18 21–28
Treatment WT 4 Male 17–18 20–25
Control P2ry6−/− 4 Male 18–20 22–29
Treatment P2ry6−/− 4 Male 18–20 20–26
I.p. injection of LPS (group 2) Control WT 4 Male 20–26 32–36
Treatment WT 4 Male 20–26 34–38
Control P2ry6−/− 4 Male 20–25 28–35
Treatment P2ry6−/− 4 Male 20–25 29–35
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Transcardial perfusion and tissue sectioning
Mice were given terminal anaesthesia (150  µl Euthatal 
i.p.) and, once unresponsive to pain, perfused tran-
scardially, through a 25-gauge needle, with 20  ml PBS, 
pH 7.4 followed by 60  ml 4% PFA, pH 7.4 using a per-
fusion pump with flow rate of 4 ml/min. Following per-
fusion, brains were removed and post-fixed overnight 
in the same solution, and cryoprotected by immersion 
in 10–30% sucrose solution until sectioning. Brain sec-
tions were cut to 20 µm thickness using a Compresstome 
VF-200 vibratome (Precisionary Instruments), collected 
on Superfrost Plus slides (Thermo Fisher) and dried 
overnight. Serial coronal sections (25  µm) through the 
whole brain were collected using a sliding microtome and 
placed in PBS as free-floating sections.
Immunostaining of brain slices
All steps were carried out at room temperature unless 
indicated otherwise. Brain slices were re-hydrated for 1 h 
in PBS and heat-mediated antigen retrieval was carried 
out at 95 °C for 20 min in citrate buffer (10 mM sodium 
citrate, 0.05% Tween 20, pH 6.0). Following washes in 
PBS (6 × 10 min), slices were permeabilized in PBS with 
0.5% Triton X-100 for 10 min followed by 1 h incubation 
in blocking solution (20% normal goat serum in PBS). 
Slices were then incubated in primary antibody solu-
tion (5% normal goat serum in PBS plus appropriate pri-
mary antibody) at 4  °C overnight. Following washes in 
PBS (6 × 10  min), slices were incubated with secondary 
antibody for 2 h, washed (6 × 10 min, PBS) and mounted 
using Vectashield mounting medium with DAPI (Vector 
Laboratories). Primary antibodies used were Anti-NeuN 
(Millipore, mouse monoclonal, 1:500 dilution), anti-
IbaI (Wako, rabbit polyclonal, 1:500 dilution) and anti-
Tyrosine Hydroxylase (Merck, rabbit polyclonal, 1:500 
dilution). Secondary antibodies were Alexa-Fluor 488 
anti-mouse, Alexa-Fluor 568 anti-rabbit and Alexa-Fluor 
633 anti-rabbit (all ThermoFisher, goat, 1:1000 dilution). 
Imaging was carried out on an Olympus FV1000 upright 
laser-scanning confocal microscope with a 60×, 1.35 NA 
oil immersion objective using 488, 559 and 635 nm laser 
lines.
Image analysis using ImageJ 1.49 software
All image analysis was carried out using ImageJ 1.49 
software. All manual counting and quantification was 
performed blinded to genotype and treatment condi-
tion. Neuronal numbers were quantified for the CA1 
and CA3 regions of the hippocampus as well as the outer 
layer of the motor cortex. Neuronal density within these 
regions was quantified by counting of neuronal cell bod-
ies within areas of fixed size. CA1 and CA3 regions were 
‘straightened’ in Fiji [26], allowing rectangles of constant 
size to be placed at the same position relative to identifia-
ble brain structures. CA1 and CA3 width was determined 
at three fixed points along their length using line inten-
sity profiles of the NeuN stain. Four brain sections were 
analyzed per animal, with both right and left sides of the 
hippocampus included in the analysis. For quantification 
of neuronal density in motor cortex, regions of interest of 
fixed size were placed randomly in anatomically matched 
sections and  NeuN+ cells counted manually. Three areas 
were counted on each side of the midline for a total of 
four sections per animal. For quantification of cell den-
sities (neuron and microglia) in SN, left and right sides 
of four anatomically matched sections were analyzed for 
each animal. Dopaminergic cells were counted as tyros-
ine-hydroxylase-positive cells in the entire substantia 
nigra pars compacta (SNpc). For the same area,  NeuN+ 
neurons and  Iba1+ microglia were counted and cell 
counts were normalized to the area.
Cell line experiments
BV-2 are a murine microglial cell line, immortalised by a 
v-raf/v-myc-carrying retrovirus [27]. BV-2 (passage < 30) 
were maintained in DMEM supplemented with 10% FBS 
(glial medium). At confluence, cells were harvested using 
0.5% trypsin in PBS, seeded at 4 ×  104 cells/well (micros-
copy) or 5 ×  104  cells/well (flow cytometry) in DMEM 
supplemented with 0.5% FBS (0.5% glial medium), and 
left to adhere for 24 h prior to treatment.
PC12 are a rat pheochromocytoma cell line [28], that 
can be differentiated into dopaminergic neuron-like 
cells [29]. PC12 were maintained in RPMI medium sup-
plemented with 10% horse serum and 5% FBS (PC12 
medium). To generate differentiated PC12, cells were 
seeded on collagen (4  μg/well) at 5 ×  104 cells/well in 
RPMI supplemented with 0.5% horse serum and 100 ng/
ml NGF, and left to differentiate for 3 days.
BV-2 cells were seeded at 1.25 ×  104 cells/well on 
TAMRA-stained (50  µM) differentiated PC12 cells. 
Mixed cultures were stimulated with LPS (100  ng/ml) 
after 24 h, and MRS2578 (1 µM) was added daily where 
indicated. After a further 72 h, cultures were stained with 
Hoechst 33342, propidium iodide and  IB4 and imaged. 
The number of TAMRA-positive BV-2 cells (BV-2 having 
phagocytosed PC12) was quantified.
Cytokine and chemokine release from microglia
Primary microglia were isolated from mixed glial cul-
tures from wild-type and  P2ry6−/− mice, and treated with 
± 100 ng/ml lipopolysaccharide for 16 h, then the extra-
cellular cell supernatant was centrifuged at 10,000 RCF 
to remove cellular debris. Supernatant was then assayed 
using an ELISA for 62 mouse cytokines and chemokines 
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as per the manufacturer’s instructions (abcam, 
ab133995). Densitometric measurements were quantified 
using ImageJ, whereby intensity values were normalised 
between membranes using positive control spots. The 
fold change ± LPS for  P2ry6+/+ and  P2ry6−/− micro-
glia was tested for significance using unpaired t tests for 
each cytokine/chemokine, followed by a Holm–Šídák 
multiple comparisons test. There were no significant dif-
ferences for any cytokine/chemokine: VEGF, VCAM-1, 
thrombopoietin, sTNF RI, sTNF RII, TNF α, TIMP-1, 
TECK, TCA-3, TARC, SDF-1 α, SCF, RANTES, P-selec-
tin, PF-4, MIP-3 α, MIP-3 β, MIP-2, MIP-1 γ, MIP-1 α, 
MIG, M-CSF, MCP-5, MCP1, lymphotactin, L-selec-
tin, LIX, leptin, leptin R, KC, IL-17, IL-13, IL-12 p70, 
IL-12 p40/70, IL-10, IL-9, IL-6, IL-4, IL-3 Rb, IL-3, IL-2, 
IL-1β, IL-1α, IGFBP-6, IGFBP-5, IGFBP-3, IFN-γ, GM-
CSF, GCSF, fractalkine, Fas ligand, eotaxin-2, eotaxin, 
CXCL16, CTACK, CRG-2, CD40, CD30 T, CD30 L, BLC 
and Axl (based on three independent experiments).
Primary cell culture experiments
Primary mixed neuronal/glial cultures were prepared 
from cerebella of postnatal days 3–5 WT and P2ry6−/− 
mouse pups as previously described [30]. Cells were 
treated with 500 ng/ml of lipopolysaccharide for 3 days. 
To assess cell viability after LPS treatment, we measured 
the rate of reduction of MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium) to formazan by the cells. 
Thus, mixed neuronal/glial cultures were incubated with 
MTT (0.58 mg/ml) for 2 h at 37 °C. Afterward, the con-
verted dye was liberated from the cells and solubilized by 
addition of dimethyl sulfoxide (DMSO), and the absorb-
ance intensity of λ = 590 nm light was measured.
Statistical analysis
All statistical analysis was carried out using GraphPad 
Prism 6 and the statistical tests are indicated in the figure 
legends.
Results
We tested whether  P2Y6R knockout (P2ry6−/−) pro-
tected against the neuronal loss induced by periph-
eral inflammation. Mice received doses of 1  µg/g LPS 
intraperitoneally (i.p.) on 4 successive days, a treat-
ment which has been shown to result in significant loss 
of neurons in the substantia nigra [31]. As expected, 
LPS-treated wild-type animals showed a significant 
reduction in the total number of tyrosine hydroxylase 
(TH)-positive dopaminergic neurons in the substantia 
nigra pars compacta (SNpc) (Fig. 1a, b). The total num-
ber of NeuN-positive neurons in this area was also 
significantly reduced in LPS-treated wild-type (WT) 
animals compared to vehicle-treated controls (Fig. 1c). 
However, the proportion of  NeuN+ neurons lost (21%) 
was less than the proportion of dopaminergic neu-
rons lost (29%), suggesting that dopaminergic neurons 
were somewhat more vulnerable to peripheral LPS 
treatment.
In contrast to wild-type mice, P2ry6−/− mice had no 
significant LPS-induced neuronal loss, measured by 
tyrosine hydroxylase or NeuN (Fig. 1b, c). Thus, genetic 
ablation of  P2Y6R completely prevents neuronal loss in 
this inflammatory model that is particularly relevant to 
PD [12, 32]. Neither genotype nor LPS had any signifi-
cant effect on microglial density in the substantia nigra 
(Fig. 2d), indicating that  P2Y6R ablation did not prevent 
neuronal loss by preventing microglial proliferation, 
(which is also one measure of microglia activation).
LPS treatment did not cause any change in the den-
sity of NeuN-positive neurons in hippocampal areas 
CA1 and CA3 or motor cortex (Fig.  2a–d), or any 
change in the width of CA1 or CA3 (Fig.  2e, f ). This 
indicates selective vulnerability (or exposure) of the 
SNpc to peripheral LPS treatment, consistent with the 
hypothesis that elevated peripheral LPS may contribute 
to neuronal loss in Parkinson’s disease [12].
To help elucidate mechanisms in vitro, we co-cultured 
BV-2 microglia with differentiated PC12 dopaminergic 
neurons [33], and found that LPS induced microglial 
phagocytosis of neurons, which was prevented by a 
specific inhibitor of  P2Y6R (1 μM MRS278) (Fig. 3a, b). 
This supports the ideas that LPS can increase microglial 
phagocytosis of neurons, and that inhibition of  P2Y6R 
can prevent this and, therefore, might have therapeutic 
potential.
To test whether P2ry6 knockout affects the LPS-
induced activation of microglia, primary microglia 
were isolated from wild-type and  P2ry6−/− mice, and 
treated ± LPS for 16  h, then cytokine release into the 
culture medium was measured using an ELISA for 62 
mouse cytokines and chemokines. However, there 
were no significant differences between wild-type and 
 P2ry6−/− microglia in the fold change in cytokine/
chemokine release induced by LPS (see “Methods”).
We have previously shown that LPS induces neuronal 
loss in primary glial–neuronal cultures via microglial 
phagocytosis [8–11], so we tested here whether this 
neuronal loss required the engulfment receptor  P2Y6R. 
We found that addition of LPS caused a loss of viabil-
ity in cultures from wild-type (WT) mice, but this was 
reduced in cultures from  P2Y6R knockout (P2ry6−/−) 
Page 5 of 9Milde et al. J Neuroinflammation          (2021) 18:225  
mice (Fig.  3c). Thus,  P2Y6R knockout is neuroprotec-
tive against LPS both in vitro and in vivo.
Discussion
We tested whether P2ry6 knockout affected LPS-induced 
neuronal loss in  vivo and in  vitro. We used a chronic 
peripheral LPS (intraperitoneal injection) model that 
has previously been described to induce dopaminergic 
neuronal loss in the substantia nigra, as indicated by 
loss of cells staining with TH, NeuN and/or MAP2 [31, 
34]. The LPS also induced inflammatory activation of 
the microglia (for the first few days after LPS), including 
particularly the expression of phagocytic genes, such as 
complement C3, and the neuronal loss was prevented 
by knockout of C3 [31, 34, 35]. This model may be 
directly relevant to human PD, as intestinal permeability 
increases early in PD, potentially allowing leakage of bac-
terial products, such as LPS into the blood and perito-
neum, and blood LPS levels increase in some PD patients 
[12, 13, 15, 36]. One source of this LPS is the gut micro-
biome, which is disturbed in PD and PD models, and may 
affect PD progression [36, 37].
We observed robust loss of dopaminergic neurons in 
the substantia nigra in wild-type mice treated with LPS; 
Fig. 1 P2ry6 knockout mice are protected against peripheral LPS-induced neuronal loss. WT and P2ry6−/− mice were injected i.p. with LPS on 4 
successive days and 14 days later the substantia nigra was sectioned and stained to quantify neuronal and microglial density. a Representative 
images of anatomically matched, anti-tyrosine hydroxylase (TH) stained sections of substantia nigra pars compacta (SNpc) in LPS-treated and 
vehicle-treated WT and P2ry6−/− mice. Scale bar: 100 µm. b TH-positive dopaminergic neurons per section in SNpc. c Relative densities of 
NeuN-positive neurons in SNpc. c Relative densities of Iba-positive microglia (or other macrophages) in SNpc. Each data point represents one 
animal and error bars represent mean ± SEM. Statistical analysis was performed using two-way ANOVA with post hoc Tukey’s multiple comparison 
test. *p < 0.05, **p < 0.01, ****p < 0.0001
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Fig. 2 Peripheral LPS treatment does not alter neuronal densities in hippocampus or prefrontal cortex. a Mouse brain slice stained for nuclei 
(with DAPI, green) and for neuronal nuclei (with anti-NeuN antibodies, magenta). Regions of interest for quantification in CA1, CA3 and cortex 
are indicated (scale-bar 500 μm).  NeuN+ neuronal densities in anatomically matched sections of b CA1 hippocampus, c CA3 hippocampus or d 
motor cortex of wild-type (WT) and P2ry6−/− mice following i.p. injection of PBS (vehicle) or LPS. Mean width of e CA1 hippocampus and f CA3 
hippocampus of same mice. Each data point represents one animal and error bars represent mean ± SEM. Statistical analysis was performed using 
two-way ANOVA, followed by Sidak-adjusted post-hoc tests, but there were no statistically significant differences
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however, P2ry6 knockout mice were protected against 
this neuronal loss. Interestingly, in wild-type mice, we 
found no evidence for LPS-induced neuronal loss in 
the cortex or the hippocampus of wild-type and P2ry6 
knockout mice. Thus, this peripheral inflammation-
driven model of dopaminergic neuronal loss in the sub-
stantia nigra appears to model the selective vulnerability 
of this neuronal population observed in PD, and lack of 
 P2Y6R protects against this neuronal loss. Consistent 
with this, we previously reported that the  P2Y6R inhibi-
tor MRS2578 prevented neuronal loss in the striatum 
of rats injected with LPS [9]. Similarly, Oliveira-Giac-
omelli et  al. [38] have recently reported that MRS2578 
prevented dopaminergic neuronal loss in the substantia 
nigra of rats injected with 6-hydroxydopamine, a model 
of PD, indicating the potential of  P2Y6R inhibitors to 
reduce neuronal loss in PD. Furthermore, Yang et  al. 
[25] reported that LPS increased  P2Y6R expression by 
microglia, and that  P2Y6R expression was increased in 
peripheral blood monocytes from PD patients relative to 
healthy controls, indicating elevated  P2Y6R expression in 
PD patients, possibly due to elevated LPS, and potentially 
inducing  P2Y6R-mediated phagocytosis.
We measured loss of neurons in the SNpc using tyros-
ine hydroxylase (TH) as a marker of dopaminergic 
neurons, and “neuronal nuclei” (NeuN) as a marker of 
Fig. 3 P2Y6R inhibition or knockout prevents LPS-induced phagocytosis and neuronal loss in culture. a Bright field and fluorescent images of 
differentiated TAMRA-stained PC12 (red), co-cultured for 3 days with  IB4-labelled BV-2 (green), nuclei stained with Hoechst 33342 (blue) ± LPS. BV-2 
phagocytosis of PC12 is visible as punctate TAMRA staining in  IB4-stained cells (white arrowheads). Representative images; scale bar = 50 µm. b 
Quantification of BV-2 phagocytosis of PC12 cells ± LPS ± MRS2578 after 3 days. c Mixed neuronal–glial cultures from cerebella of wild-type (WT) 
or P2ry6−/− mice were treated for 3 days with ± 500 ng/ml LPS, then cell viability was measured by MTT assay. Data represent mean ± SEM of at 
least three independent experiments. Statistical analysis was performed using one-way ANOVA with post hoc Tukey’s multiple comparison test. 
***p < 0.001 compared to vehicle-treated control (first bar). +++p < 0.001 compared to LPS-treated vehicle control (second bar). #p < 0.05 compared 
to LPS-treated wild-type condition (second bar)
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total neurons. However, Cannon and Greenamyre [39] 
reported that a proportion of  TH+ cells in the SNpc did 
not express detectable NeuN, and Ünal-Çevik et al. [40] 
reported that some cortical neurons lost detectable NeuN 
hours after brain ischaemia but had intact nuclei, imply-
ing that live neurons could lose NeuN staining. However, 
they attributed this to caspase-3 activation in these cells, 
and translocation of NeuN to the cytoplasm; thus, they 
concluded that counting  NeuN+ cells could still be used 
to measure neuronal loss/death. TH expression can also 
vary in neurons [41] and can fall in Parkinson’s disease 
[42], but there are very few reports of neurons losing 
detecting TH staining while remaining live neurons, and 
as TH is required for dopamine synthesis, cells without 
TH can not be dopaminergic neurons [41]. Our finding 
that both  TH+ and  NeuN+ cells in the SNpc are reduced 
by LPS and this is prevented by  P2Y6R knockout, sup-
ports the conclusion that the reduction in neuronal 
numbers is due to cell loss mediated by  P2Y6R, but we 
cannot rule out that some of the neurons dedifferentiated 
and this was prevented by  P2Y6R knockout. Similarly, 
as we did not directly measure microglial phagocytosis 
of neurons in vivo, we cannot be sure that the neuronal 
loss was due to microglial phagocytosis. However, this 
interpretation would be consistent with the mechanism 
of LPS-induced neuronal loss previously characterized 
in vitro and in vivo, and consistent with the  P2Y6R being 
required for microglial phagocytosis of neurons [8, 9, 18].
In vitro, LPS induced BV-2 microglial phagocyto-
sis of dopaminergic PC12 cells that was prevented by 
inhibition of  P2Y6R, consistent with our previous find-
ings [33]. P2ry6 knockout protected against neuronal 
loss induced by LPS in primary glial–neuronal cul-
tures. We have previously shown that this neuronal loss 
induced by LPS is mediated by microglial phagocytosis 
of stressed-but-viable neurons [8–11], and the results 
here are consistent with this being mediated by the 
engulfment receptor  P2Y6R.
Overall, our findings indicate that the  P2Y6 receptor 
contributes to neuronal loss under inflammatory con-
ditions. This suggests that a  P2Y6R antagonist might 
prevent neuronal loss in Parkinson’s and other diseases 
with inflammatory neuronal loss.
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